Treatment for Chronic Prostatitis
For chronic bacterial prostatitis, ciprofloxacin 500 mg twice daily for 4-6 weeks is the first-line treatment due to its superior prostatic tissue penetration and documented efficacy. 1
Classification of Prostatitis
Prostatitis is classified into four categories:
- Acute bacterial prostatitis
- Chronic bacterial prostatitis (CBP)
- Chronic nonbacterial prostatitis (CNP)/chronic pelvic pain syndrome (CPPS) - accounts for >90% of cases
- Asymptomatic inflammatory prostatitis
Diagnostic Approach
- Meares and Stamey 2- or 4-glass test is strongly recommended for diagnosis 1
- Midstream urine culture to guide antibiotic selection
- Blood culture and complete blood count in acute cases
- Transrectal ultrasound in selected cases to rule out prostatic abscess
Treatment Algorithm
1. Chronic Bacterial Prostatitis (CBP)
2. Chronic Nonbacterial Prostatitis/Chronic Pelvic Pain Syndrome (CNP/CPPS)
- Alpha-blockers: Alfuzosin, doxazosin, tamsulosin, or terazosin 3
- More effective with longer duration of therapy in alpha-blocker-naïve patients 4
- Trial of antibiotics: 4-6 week course despite negative cultures 5
- Non-pharmacological interventions:
Special Considerations
For Atypical Pathogens
- Chlamydia trachomatis: Azithromycin 1.0-1.5 g single dose or doxycycline 100 mg twice daily for 7 days 1
- Mycoplasma genitalium: Azithromycin 500 mg on day 1, then 250 mg for 4 days; if macrolide-resistant, use moxifloxacin 400 mg daily for 7-14 days 1
For Patients with Renal Impairment
Ciprofloxacin dosage adjustment based on creatinine clearance 2:
- 30-50 mL/min: 250-500 mg every 12 hours
- 5-29 mL/min: 250-500 mg every 18 hours
- Hemodialysis/peritoneal dialysis: 250-500 mg every 24 hours (after dialysis)
Treatment Pitfalls and Caveats
Inadequate treatment duration: Ensure complete 4-6 week course for chronic infections, even when symptoms improve early 1
Poor antibiotic selection: Choose antibiotics with good prostatic tissue penetration (fluoroquinolones have penetration ratios up to 4:1) 4
Overlooking complications: Rule out prostatic abscess in patients who fail to respond to appropriate antibiotic therapy 1
Fluoroquinolone side effects: FDA has issued warnings about side effects affecting tendons, muscles, joints, nerves, and central nervous system 1
Overlooking atypical pathogens: Consider testing for Chlamydia trachomatis and Mycoplasma species in resistant cases 1
Follow-up monitoring: Clinical reassessment after 2 weeks to evaluate symptom improvement and urine culture at the end of treatment to confirm eradication 1
Conclusion for Clinical Practice
The treatment of chronic prostatitis requires a targeted approach based on proper classification. For bacterial prostatitis, fluoroquinolones (particularly ciprofloxacin) remain the cornerstone of therapy due to their excellent prostatic penetration. For chronic nonbacterial prostatitis/CPPS, a combination of alpha-blockers, trial of antibiotics, and non-pharmacological interventions should be considered. Regardless of the type, adequate treatment duration is crucial for successful outcomes.